Characterizing T cell responses in chikungunya virus infection

Active Grant Awarded

Award ID
F31AI197833
Recipient
Awarding agency
Obligated
$43,489

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 11% complete
Place of performance
La Jolla, CA 92093, USA

Award details come from USAspending.gov.

Description

Abstract
Chikungunya virus (CHIKV) is a RE-emerging neglected tropical alphavirus transmitted by mosquitoes and is known for its capability to induce debilitating chronic arthralgia and inflammation in patients for months to years post-infection. Despite recurrent outbreaks and ongoing vaccine development efforts, our understanding of immune responses to CHIKV in human populations experiencing chronic disease is largely limited. Additionally, even less work has been done to study immune responses to other arthritogenic alphaviruses, which is a sub-group of alphaviruses that are known to also cause arthritis-like symptoms post-infection, similar to CHIKV. To address a critical GAP in our understanding of the development of chronic disease, the overall goal of this study is to comprehensively characterize immune responses, particularly T-cell responses, to CHIKV and other alphaviruses in individuals with long-term arthritis-like symptoms post-infection. My previous work has shown that T cells play an essential role in CHIKV pathogenesis. Using EX vivo peptide-based T cell stimulation and high-resolution spectral flow cytometry, I found that CHIKV-specific CD4+ T cells are more frequent in the peripheral blood of patients with chronic symptoms as opposed to those who have recovered. Previous studies in mice and non-human primates have also suggested a pathogenic role of CD4+ T cells in disease pathogenesis. Building on this intriguing observation, I hypothesize that CD4+ T cells play a pathogenic role in CHIKV infection in humans and could be responsible for the development of chronic arthritis-like symptoms and inflammation. To test this hypothesis, I propose two specific aims for the study. First, I intend to better characterize the transcriptional profile and functional phenotype of CHIKV-specific memory effector CD4+ T cells in individuals with chronic disease by performing high dimensional single-cell RNA sequencing of antigen-specific effector and regulatory CD4+ T cells. Second, I aim to determine whether CHIKV-specific T cells are cross-reactive with other arthritogenic and encephalitic alphaviruses that CO-circulate with CHIKV by first mapping cross-reactive regions in other alphaviruses and assessing T cell phenotype in an in vitro and EX vivo T cell assay. Overall, my project will provide a comprehensive landscape of the T cell immune profile in CHIKV and other alphavirus infections and deepen our understanding of how T cell responses are modulated in chronic diseases.

Quick answers

Who received award F31AI197833?

F31AI197833 was awarded to University Of California, San Diego by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 24, 2026.

How much is award F31AI197833 worth?

$43,489 has been obligated on F31AI197833.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award